NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo

(2010) Thorsten Fuereder et al.   CANCER LETTERS

RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase

(2010) Kyung-Hun Lee et al.   CANCER LETTERS

PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling

(2010) E. Halilovic et al.   CANCER RESEARCH

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

(2010) C. O'Brien et al.   CLINICAL CANCER RESEARCH

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo

(2010) Z. A. Wainberg et al.   CLINICAL CANCER RESEARCH

Subtle variations in Pten dose determine cancer susceptibility

(2010) Andrea Alimonti et al.   NATURE GENETICS

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

(2009) Michael Hedvat et al.   CANCER CELL

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

(2009) S. Wee et al.   CANCER RESEARCH

Gastric cancer

(2009) Henk H Hartgrink et al.   LANCET

Inhibitor hijacking of Akt activation

(2009) Tatsuya Okuzumi et al.   Nature Chemical Biology

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

(2009) M. L. Sos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation

(2009) D. J. Gough et al.   SCIENCE

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3

(2008) E. A. Nelson et al.   BLOOD

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

(2008) N. T. Ihle et al.   CANCER RESEARCH

Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation

(2008) Audrey Carrière et al.   CURRENT BIOLOGY

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE